Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL305050 | 1.00 | TP53 (0.38) | TP53CA12CA14DGAT1CA1 | |
| SCHEMBL1332536 | 1.00 | TP53 (0.38) | TP53CA12CA14DGAT1CA1 | |
| Alcohol SCHEMBL8207414 | 0.91 | CA1 (0.36) | TP53CA12CA14DGAT1CA1 | |
| Propionic Acid SCHEMBL3457303 | 0.87 | FFAR3 (0.42) | TP53CA12CA14CA1CA2 | |
| SCHEMBL7260792 | 0.84 | CA12 (0.33) | TP53CA12CA14DGAT1CA1 | |
| SCHEMBL8030378 | 0.82 | HTT (0.40) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL19407016 | 0.82 | HTT (0.40) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL8028869 | 0.82 | HTT (0.40) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL1845280 | 0.82 | HTT (0.40) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL11855010 | 0.81 | CA1 (0.39) | CA12CA14DGAT1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146047-A1 | MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-28 | — | — | US | disclosed |
| EP-4680611-A1 | MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2026-01-21 | — | — | EP | disclosed |
| WO-2025235363-A1 | CYCLIN-DEPENDENT KINASE 4 DEGRADERS | BLUEPRINT MEDICINES CORPORATION (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2025-09-25 | — | — | US | disclosed |
| EP-4149941-B1 | CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOF | ALGEN BIOTECHNOLOGIES INC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250223291-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION | 2025-07-10 | — | — | US | disclosed |
| US-12281079-B2 | Quinoline derivatives, processes for their preparation and uses thereof for the treatment of cancer | LEAD DISCOVERY CENTER GMBH (DE) | 2025-04-22 | — | — | US | disclosed |
| US-12264152-B2 | Certain chemical compositions and methods of use thereof | ALGEN BIOTECHNOLOGIES, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| WO-2024189597-A1 | MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-09-19 | — | — | WO | disclosed |
| US-20240309016-A1 | MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-09-19 | — | — | US | disclosed |
| US-6495566-B2 | POTENT ANTAGONISTS AT THE STRYCHNINE INSENSITIVE GLYCINE BINDING SITE ASSOCIATED WITH THE N-METHYLASPARTIC ACID RECEPTOR COMPLEX | SMITHKLINE BEECHAM CORPORATION | 2002-12-17 | — | — | US | disclosed |
| US-20020169186-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS GLYCINE ANTAGONISTS | DI FABIO ROMANO (IT) | 2002-11-14 | — | — | US | disclosed |
| US-6413985-B1 | SELECTIVE ANTAGONISTS FOR THE STRYCHNINE INSENSITIVE GLYCINE BINDING SITE ASSOCIATED WITH THE NMDA RECEPTOR COMPLEX. | SMITHKLINE BEECHAM CORPORATION | 2002-07-02 | — | — | US | disclosed |
| US-20020052391-A1 | Tetrahydroquinoline derivatives as glycine antagonists | DI FABIO ROMANO (IT) | 2002-05-02 | — | — | US | disclosed |
| US-6362199-B1 | CENTRAL NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2002-03-26 | — | — | US | disclosed |
| CN-1311785-A | Tetrahydroquinoline derivatives as glycine antagonists | GLAXO WELLCOME SPA (IT) | 2001-09-05 | — | — | CN | disclosed |
| EP-1087981-A2 | PRENYL TRANSFERASE INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S. (FR) | 2001-04-04 | — | — | EP | disclosed |
| EP-1086093-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS GLYCINE ANTAGONISTS | GLAXO WELLCOME S.p.A. (IT) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999065922-A2 | PRENYL TRANSFERASE INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S. (FR) | 1999-12-23 | — | — | WO | disclosed |
| WO-1999064411-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS GLYCINE ANTAGONISTS | GLAXO WELLCOME SPA (IT) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052391-A1 | Tetrahydroquinoline derivatives as glycine antagonists | GLRB, GLRA2, GLRA1 | TP53 4775/4885CA12 3784/4885CA14 3865/4885 |
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | TP53 1257/4885CA12 3487/4885CA14 3027/4885 |
| US-20250223291-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | ERBB2, MERTK, ABL1 | TP53 312/4885CA12 3754/4885CA14 3868/4885 |
| US-12281079-B2 | Quinoline derivatives, processes for their preparation and uses thereof for the treatment of cancer | AVPR2, AVPR1A, VHL | TP53 10/4885CA12 1285/4885CA14 1722/4885 |
| US-20020169186-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS GLYCINE ANTAGONISTS | GLRA1, GRM1, GNMT | TP53 4734/4885CA12 3055/4885CA14 2969/4885 |
| US-20240309016-A1 | MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF | HCRTR2, HCRTR1, NTSR2 | TP53 4885/4885CA12 2202/4885CA14 2932/4885 |
| US-20260146047-A1 | MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF | HCRTR2, HCRTR1, NPY1R | TP53 4883/4885CA12 2594/4885CA14 2928/4885 |
| US-12264152-B2 | Certain chemical compositions and methods of use thereof | CDK9, CDK19, CDK6 | TP53 63/4885CA12 1955/4885CA14 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.